8-K: Bausch + Lomb Amends CEO's Severance and Performance Equity Terms

Bausch + Lomb Corporation has amended CEO Brenton L. Saunders' employment agreement and performance stock unit award, tying a significant portion of his compensation to long-term share price and Adjusted EBITDA targets through 2029.

Summary

• Bausch + Lomb Corporation amended its employment agreement with CEO Brenton L. Saunders on July 21, 2025.
• The amendment limits Mr. Saunders' "good reason" severance rights by removing a provision tied to the timing of the spin-off from Bausch Health Companies Inc.
• An amended and restated award agreement for Mr. Saunders' New Hire Performance Stock Units (PSUs), originally granted on February 23, 2023, was also entered into.
• These New Hire PSUs will now vest and pay out between 120% and 330% of the target award on February 23, 2029.
• Payout is contingent on achieving specified share-price hurdle goals ranging from US$26.57 per share to US$39.06 per share.
• A new cumulative Adjusted EBITDA performance modifier for the 2025-2028 fiscal years will adjust the payout by -40% to +40% of the share-price hurdle payout.
• The vesting is subject to Mr. Saunders' continued employment through the New Performance End Date of February 23, 2029, with certain exceptions.

Sentiment

Score: 7

Explanation: The filing indicates a strong commitment to retaining the CEO and aligning his long-term compensation with significant shareholder value creation and operational performance. The performance targets are ambitious, suggesting confidence in future growth. The limitation of severance rights related to the spin-off also provides clarity and stability.

Positives

• CEO Brenton L. Saunders' long-term incentives are now more directly aligned with significant share price appreciation and cumulative Adjusted EBITDA performance through February 2029.
• The removal of the spin-off timing as a severance trigger may provide greater stability regarding CEO tenure post-spin-off.
• The performance targets for PSUs are clearly defined, providing transparency on the metrics for executive compensation.

Negatives

• The specific cumulative Adjusted EBITDA targets are not disclosed, limiting full transparency on the difficulty of this performance modifier.
• The potential for a 330% payout of target PSUs could be viewed as substantial compensation, depending on the initial target value.

Risks

• The achievement of the share-price hurdles and Adjusted EBITDA targets is subject to market conditions and company performance, which are inherently uncertain.
• Failure to meet the performance targets could result in a lower or no payout for the CEO, potentially impacting executive motivation, though this is a standard risk for performance-based compensation.

Future Outlook

The company has set clear long-term performance incentives for its CEO, extending through February 2029, based on achieving specific share price appreciation and cumulative Adjusted EBITDA targets for the 2025-2028 fiscal years. This indicates a strategic focus on sustained growth and shareholder value creation over the next several years.

Management Comments

• The company entered into an amendment to the employment agreement with Brenton L. Saunders to limit the scope of his good reason severance rights relating to a spin-off.
• The company and Mr. Saunders also entered into an amended and restated award agreement for his New Hire PSUs, aligning his compensation with long-term share price and Adjusted EBITDA performance.

Industry Context

This amendment reflects a common trend in executive compensation, where companies increasingly tie a significant portion of CEO pay to long-term performance metrics such as share price and profitability (e.g., Adjusted EBITDA). This structure aims to align executive incentives with shareholder interests and encourage sustained value creation, particularly in the healthcare and pharmaceutical sectors where long development cycles and market dynamics necessitate a long-term view.

Comparison to Industry Standards

• The use of performance stock units (PSUs) with multi-year vesting periods and performance hurdles (share price and Adjusted EBITDA) is a standard practice for long-term incentive plans for CEOs in large, publicly traded companies, including those in the pharmaceutical and medical device industries like Johnson & Johnson, Medtronic, or Abbott Laboratories.
• The specific share price hurdles (US$26.57 to US$39.06) represent significant appreciation from current levels (assuming the stock is below these, which is typical for performance targets), similar to ambitious targets set by peers aiming for substantial shareholder returns.
• The inclusion of an Adjusted EBITDA modifier is also common, balancing market-based performance (share price) with operational profitability, a practice seen across various industries to ensure financial health alongside market valuation.
• The modification of severance terms related to a spin-off is a specific adaptation to Bausch + Lomb's unique corporate structure, given its recent separation from Bausch Health Companies Inc., and is a tailored approach to retain key leadership during transitional periods, a strategy also observed in other complex corporate restructurings.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased shareholder value if the company achieves the ambitious share price and Adjusted EBITDA targets, as the CEO's incentives are directly tied to these outcomes. The clarity on CEO retention post-spin-off also reduces uncertainty.

Next Steps

• The full text of the employment agreement amendment and the New Hire PSU award amendment will be filed with the Company's Quarterly Report on Form 10-Q for the quarter ending September 30, 2025.

Key Dates

Recommendation

The filing details a significant amendment to the CEO's compensation structure, aligning his long-term incentives with ambitious share price and Adjusted EBITDA targets. This is generally a positive development for shareholder alignment and executive retention. However, without specific financial results or new strategic initiatives, it primarily reinforces existing long-term goals rather than introducing new catalysts for immediate price movement. The stock's performance will depend on the actual achievement of these targets, which are several years out. Therefore, a "hold" recommendation is appropriate, as the news is positive for long-term alignment but does not provide an immediate strong buy signal based solely on this compensation update.

Keywords

Bausch + Lomb, BLCO, SEC filing, 8-K, CEO compensation, executive compensation, performance stock units, PSUs, Brenton L. Saunders, employment agreement, Adjusted EBITDA, share price targets, corporate governance, severance rights